You have 9 free searches left this month | for more free features.

JAK-inhibitor

Showing 1 - 25 of 7,638

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Rheumatoid Arthritis Trial (Baricitinib 4 MG, Placebo)

Not yet recruiting
  • Rheumatoid Arthritis
  • Baricitinib 4 MG
  • Placebo
  • (no location specified)
Jul 27, 2023

Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)

Not yet recruiting
  • Myelofibrosis
  • Moderate Thrombocytopenia
  • (no location specified)
Jul 31, 2023

Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)

Recruiting
  • Acneiform Eruptions
  • Cream containing JAK Inhibitor
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Jun 20, 2022

Active Non-anterior Non-infectious Uveitis Trial (Baricitinib 4 MG)

Not yet recruiting
  • Active Non-anterior Non-infectious Uveitis
  • Baricitinib 4 MG
  • (no location specified)
Dec 7, 2022

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Recruiting
  • Rheumatoid Arthritis
  • Upadacitinib <15 MG [Rinvoq]
  • Montpellier, France
    CHU de Montpellier
Jan 12, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Rheumatoid Arthritis Trial (Upadacitinib, Adalimumab)

Not yet recruiting
  • Rheumatoid Arthritis
  • (no location specified)
Nov 29, 2021

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Greifswald, Halle (Saale) (Fedratinib Oral Capsule [Inrebic], Nivolumab)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Greifswald, Germany
  • +1 more
Jun 15, 2022

Dermatomyositis, Adult Type Trial in Xi'an (JAK Inhibitor)

Recruiting
  • Dermatomyositis, Adult Type
  • JAK Inhibitor
  • Xi'an, Shaanxi, China
    Department of Rheumatology, the First Affiliated Hospital of Xi'
Jul 15, 2021

Graft Vs Host Disease, Graft-versus-host-disease, GVHD Trial in Saint Louis (Ruxolitinib)

Not yet recruiting
  • Graft Vs Host Disease
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 18, 2023

Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

Recruiting
  • Rheumatoid Arthritis
  • +4 more
  • filgotinib 200mg/day
  • subcutaneous tocilizumab 162mg/biweekly
  • Nagasaki, Japan
    Nagasaki University Hospital
Oct 23, 2021

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 18, 2022

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Myelofibrosis Trial in Canton (Jaktinib Hydrochloride Tablet)

Recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • Canton, Ohio
    Site 01
Aug 18, 2022

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +3 more
Oct 5, 2022

T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Ruxolitinib)

Not yet recruiting
  • T-Cell Large Granular Lymphocyte Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Oct 20, 2022

Myelofibrosis Trial in Worldwide (Ruxolitinib)

Completed
  • Myelofibrosis
  • Winter Park, Florida
  • +17 more
Jan 10, 2022

Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)

Active, not recruiting
  • Myelofibrosis
  • Long-term Follow-up
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Graft-versus-host-disease, Graft Vs Host Disease Trial in Saint Louis (Baricitinib)

Recruiting
  • Graft-versus-host-disease
  • Graft Vs Host Disease
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 4, 2022

Rheumatoid Arthritis Trial in Abu Dhabi (Anti-TNF, JAK inhibitor)

Not yet recruiting
  • Rheumatoid Arthritis
  • Abu Dhabi, United Arab Emirates
    Abu Dhabi Stem Cells Center
May 17, 2022

Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

Active, not recruiting
  • Chronic Graft vs Host Disease
  • Chronic Graft-Versus-Host Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 29, 2022

Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
May 19, 2022